Resolving the atomic level activation mechanisms of lecithin-cholesterol acyltransferase-targeted therapeutic agents utilising a novel combination of modern computational and experimental techniques
Description of the granted funding
Lecithin-cholesterol acyltransferase (LCAT) is one of the key enzymes in the metabolism of high-density lipoproteins (HDLs). This research project resolves the unclear activation mechanism of LCAT enzyme by utilizing therapeutic HDL-mimicking nanodiscs and small positive allosteric modulators. The study combines in a new way the state-of-the-art computational and experimental methods to achieve an atomistic description of how LCAT enzyme interacts with its activating HDL-mimetic nanodiscs and positive allosteric modulators, and how these therapeutics mechanistically activate LCAT. In addition, the mechanistic insights acquired during the project will be translated to more potent in vivo properties. The results contribute to the development of new therapeutic agents against dyslipidemic conditions. In addition, it provides a new computational and experimental platform for studying the structure and function of therapeutic nanodiscs in different contexts.
Show moreStarting year
2022
End year
2027
Granted funding
Related funding decisions
372121
Research costs of Academy Research Fellows(2025)
200 000 €
353815
Research costs of Academy Research Fellows(2022)
300 000 €
Funder
Research Council of Finland
Funding instrument
Academy research fellows
Decision maker
Scientific Council for Biosciences, Health and the Environment
30.05.2022
30.05.2022
Other information
Funding decision number
350636
Fields of science
Pharmacy
Research fields
Farmasia
Identified topics
pharmacy, biomedicine